Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel antihypertensive agents.

C Sierra1, Luis M Ruilope

  • 1Unidad de Hipertensión, Hospital Doce de Octubre, Madrid, Spain.

Expert Opinion on Investigational Drugs
|July 23, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.

Nature medicine·2024
Same author

Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study.

Pharmaceuticals (Basel, Switzerland)·2024
Same author

Urinary extracellular vesicles as a monitoring tool for renal damage in patients not meeting criteria for chronic kidney disease.

Journal of extracellular biology·2024
Same author

Resistant Hypertension and Mortality: An Observational Cohort Study.

Hypertension (Dallas, Tex. : 1979)·2024
Same author

Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes.

ESC heart failure·2024
Same author

Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.

Nature medicine·2024
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Managing cardiovascular risk factors like high blood pressure and diabetes through integrated interventions, including new antihypertensive drugs, can reduce cardiovascular diseases.

Area of Science:

  • Cardiovascular medicine and public health.

Background:

  • Coronary heart disease (CHD) and cerebrovascular disease are leading causes of mortality in developed nations.
  • Prevalence is linked to risk factors: hypertension, smoking, dyslipidemia, and diabetes.

Purpose of the Study:

  • To explore integrated strategies for managing cardiovascular (CV) risk factors.
  • To evaluate the potential of novel antihypertensive drugs in reducing CV diseases.

Main Methods:

  • Review of current management strategies for CV risk factors.
  • Focus on novel antihypertensive drugs targeting the renin-angiotensin-aldosterone system.
  • Analysis of drugs with pleiotropic effects (cholesterol reduction, improved insulin resistance/glucose tolerance).

Main Results:

Related Experiment Videos

  • Integrated management of multiple CV risk factors is crucial.
  • New antihypertensive drugs offer potential for comprehensive CV risk reduction.
  • Targeting the renin-angiotensin-aldosterone system and addressing metabolic factors shows promise.

    • Conclusions:

    • An integrated intervention strategy is essential for effective CV disease management.
    • Novel pharmacological approaches can simultaneously address hypertension and other CV risk factors.
    • Reducing the burden of cardiovascular and cerebrovascular diseases requires a multi-faceted approach.